JP2019511582A5 - - Google Patents

Download PDF

Info

Publication number
JP2019511582A5
JP2019511582A5 JP2019505332A JP2019505332A JP2019511582A5 JP 2019511582 A5 JP2019511582 A5 JP 2019511582A5 JP 2019505332 A JP2019505332 A JP 2019505332A JP 2019505332 A JP2019505332 A JP 2019505332A JP 2019511582 A5 JP2019511582 A5 JP 2019511582A5
Authority
JP
Japan
Prior art keywords
composition
porous silicon
silicon material
item
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019505332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511582A (ja
JP7093955B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/027772 external-priority patent/WO2017181115A1/en
Publication of JP2019511582A publication Critical patent/JP2019511582A/ja
Publication of JP2019511582A5 publication Critical patent/JP2019511582A5/ja
Priority to JP2022094681A priority Critical patent/JP2022121463A/ja
Application granted granted Critical
Publication of JP7093955B2 publication Critical patent/JP7093955B2/ja
Priority to JP2024064709A priority patent/JP2024094359A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019505332A 2016-04-14 2017-04-14 治療剤の送達のためのケイ酸金属塩を含むポーラスシリコン物質 Active JP7093955B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022094681A JP2022121463A (ja) 2016-04-14 2022-06-10 治療剤の送達のためのケイ酸金属塩を含むポーラスシリコン物質
JP2024064709A JP2024094359A (ja) 2016-04-14 2024-04-12 治療剤の送達のためのケイ酸金属塩を含むポーラスシリコン物質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322782P 2016-04-14 2016-04-14
US62/322,782 2016-04-14
PCT/US2017/027772 WO2017181115A1 (en) 2016-04-14 2017-04-14 Porous silicon materials comprising a metal silicate for delivery of therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022094681A Division JP2022121463A (ja) 2016-04-14 2022-06-10 治療剤の送達のためのケイ酸金属塩を含むポーラスシリコン物質

Publications (3)

Publication Number Publication Date
JP2019511582A JP2019511582A (ja) 2019-04-25
JP2019511582A5 true JP2019511582A5 (enExample) 2020-05-28
JP7093955B2 JP7093955B2 (ja) 2022-07-01

Family

ID=60042009

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019505332A Active JP7093955B2 (ja) 2016-04-14 2017-04-14 治療剤の送達のためのケイ酸金属塩を含むポーラスシリコン物質
JP2022094681A Withdrawn JP2022121463A (ja) 2016-04-14 2022-06-10 治療剤の送達のためのケイ酸金属塩を含むポーラスシリコン物質
JP2024064709A Pending JP2024094359A (ja) 2016-04-14 2024-04-12 治療剤の送達のためのケイ酸金属塩を含むポーラスシリコン物質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022094681A Withdrawn JP2022121463A (ja) 2016-04-14 2022-06-10 治療剤の送達のためのケイ酸金属塩を含むポーラスシリコン物質
JP2024064709A Pending JP2024094359A (ja) 2016-04-14 2024-04-12 治療剤の送達のためのケイ酸金属塩を含むポーラスシリコン物質

Country Status (7)

Country Link
US (1) US20210177770A1 (enExample)
EP (1) EP3442540A4 (enExample)
JP (3) JP7093955B2 (enExample)
CN (2) CN114949250A (enExample)
AU (2) AU2017250300B2 (enExample)
CA (1) CA3021001A1 (enExample)
WO (1) WO2017181115A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773730A4 (en) 2018-03-27 2021-12-29 The Regents of The University of California Drug delivery formulations
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
JP7335078B2 (ja) * 2019-02-21 2023-08-29 アサヒグループ食品株式会社 ペプチド含有物を含む組成物の変色抑制方法、並びに粉末組成物、顆粒、及び錠剤
JP7320303B2 (ja) * 2019-02-22 2023-08-03 レモネックス インコーポレイテッド 免疫活性もしくは癌の予防または治療用の医薬組成物
EP3714879A1 (en) 2019-03-28 2020-09-30 Sisaf Ltd Structured encapsulated silicon-containing particles
GB201904336D0 (en) * 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
GB201904334D0 (en) 2019-03-28 2019-05-15 Sisaf Ltd Carrier system for preparing herbaceous extracts
GB201904337D0 (en) * 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
GB202110644D0 (en) * 2021-07-23 2021-09-08 Sisaf Ltd Improved nucleic acid vector particles
CN114983977B (zh) * 2022-06-30 2023-03-10 浙江大学 铜-聚多巴胺共修饰的多孔硅颗粒及其制备方法和应用
CN116570721A (zh) * 2023-02-06 2023-08-11 四川农业大学 一种t-705@msn-rvg脑内药物递送载体及其制备方法
CN116510003B (zh) * 2023-06-20 2023-10-20 中国人民解放军军事科学院军事医学研究院 一种负载鼠疫菌rF1-V10蛋白的锰基纳米颗粒疫苗及其在抗鼠疫菌中的应用
WO2025098983A1 (en) * 2023-11-07 2025-05-15 Evonik Operations Gmbh Rna storage and delivery

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5130307A (en) 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5194447A (en) 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
JPH07216256A (ja) * 1994-01-28 1995-08-15 Suzuki Yushi Kogyo Kk 着色微粒子とその製造方法
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
GB0118689D0 (en) * 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
WO2003018573A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin 29-enols
EP1419153A1 (en) 2001-08-22 2004-05-19 Wyeth Rapamycin dialdehydes
AU2003208935A1 (en) 2002-02-07 2003-09-02 The Regents Of The University Of California Optically encoded particles
US7433811B2 (en) 2003-05-06 2008-10-07 The Regents Of The University Of California Direct patterning of silicon by photoelectrochemical etching
US7563451B2 (en) * 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
AU2004308380A1 (en) 2003-12-22 2005-07-14 The Regents Of The University Of California Optically encoded particles, system and high-throughput screening
AU2004308379A1 (en) 2003-12-22 2005-07-14 The Regents Of The University Of California Optically encoded particles with grey scale spectra
EP1817003B1 (en) 2004-10-29 2018-02-21 The Regents of The University of California Porous silicon microparticles for drug delivery to the eye
US20140336514A1 (en) * 2005-08-05 2014-11-13 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
GB0519391D0 (en) * 2005-09-22 2005-11-02 Aion Diagnostics Ltd Imaging agents
US8916198B2 (en) * 2006-04-25 2014-12-23 Washington State University Mesoporous calcium silicate compositions and methods for synthesis of mesoporous calcium silicate for controlled release of bioactive agents
KR20160021307A (ko) 2007-07-10 2016-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법
EP2427179A4 (en) * 2009-05-04 2013-09-11 Psivida Inc POROUS SILICON MEDICATION ELUTING PARTICLES
CN103687590A (zh) * 2011-04-28 2014-03-26 Stc·Unm公司 用于靶向给药的多孔纳米颗粒支撑脂双层（原始细胞）及其使用方法
JP6144679B2 (ja) * 2011-08-02 2017-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生細胞干渉法を介した急速超並列単細胞薬物反応測定法
CA2849378A1 (en) * 2011-09-21 2013-03-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nano delivery systems for sirna
US20150272885A1 (en) * 2011-10-14 2015-10-01 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
CN102552972A (zh) * 2011-12-22 2012-07-11 南京工业大学 金属离子修饰介孔氧化硅及其制备方法
WO2014130998A1 (en) 2013-02-25 2014-08-28 Spinnaker Biosciences, Inc. Surface functionalized porous silicon
WO2014201276A1 (en) * 2013-06-12 2014-12-18 The Methodist Hospital Polycation-functionalized nanoporous silicon carrier for systemic delivery of gene silencing agents
US11400032B2 (en) * 2013-12-20 2022-08-02 Colgate-Palmolive Company Tooth whitening oral care product with core shell silica particles
BR112016013531A8 (pt) * 2013-12-20 2020-05-19 Colgate Palmolive Co composição de cuidado oral

Similar Documents

Publication Publication Date Title
JP2019511582A5 (enExample)
Zhang et al. Inhibiting methicillin-resistant Staphylococcus aureus by tetrahedral DNA nanostructure-enabled antisense peptide nucleic acid delivery
JP7586883B2 (ja) 免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用
ES2909180T3 (es) Vacunas de ácido nucleico
Patwa et al. Hybrid lipid oligonucleotide conjugates: synthesis, self-assemblies and biomedical applications
TWI335352B (en) Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
JP2022542389A (ja) 拘束された脂質を含むナノ材料およびその使用
US20180028686A1 (en) Protocells for Plasmid and RNP Delivery in the Treatment of Cancer and Other Disease States
Cao et al. Protamine sulfate–nanodiamond hybrid nanoparticles as a vector for MiR-203 restoration in esophageal carcinoma cells
US20040220132A1 (en) Treatment of neurodegenerative disease through intracranial delivery of siRNA
RU2015104763A (ru) Олигонуклеотиды для введения изменения в последовательность молекулы целевой рнк в живой клетке
KR20200028997A (ko) 올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법
US20040162255A1 (en) Treatment of neurodegenerative disease through intracranial delivery of siRNA
JP2022532078A (ja) 皮膚及び創傷のための組成物並びにその使用の方法
JP2015523082A5 (enExample)
CN111787912A (zh) 用于核酸分子递送的纳米颗粒-水凝胶复合物
JP2021504335A (ja) フェニルケトン尿症の治療用のフェニルアラニンヒドロキシラーゼをコードするポリヌクレオチド
Andrea et al. Adsorption of oligo-DNA on magnesium aluminum-layered double-hydroxide nanoparticle surfaces: Mechanistic implication in gene delivery
Kizer et al. A molecular hero suit for in vitro and in vivo DNA nanostructures
AU2021377895A1 (en) Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
JP2010509241A5 (enExample)
Gan et al. The biology of exosomes and exosomal non-coding RNAs in cardiovascular diseases
Pandey et al. Nanoparticles Mediated Gene Knockout Through miRNA Replacement: Recent Progress and Challenges
Huang et al. Functional gold nanoparticles for analysis and delivery of nucleic acids
Ubale et al. Pulmonary administration of microparticulate antisense oligonucleotide (ASO) for the treatment of lung inflammation